This is significant. The Classification 2 limitations had pushed people towards unregulated grey-market sources. The reversal reopens the respectable compounding pathway for peptides like thymosin alpha-one and others.There is now no confirmed rationalization. Regulatory scrutiny is just one possible factor staying talked over within the sector, bu